Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Williams, J. A., Hyland, R., Jones, B., Smith, D. A., Hurst, S. I., Goosen, T. C., Peterkin, V. C., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 929 · see citing works

Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily

Mackenzie, P. I., Walter Bock, K., Burchell, B., Guillemette, C., Ikushiro, S.-I., Iyanagi, T., Miners, J. O., Owens, I. S., & Nebert, D. W. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000173483.13689.56 · Cited by 821 · see citing works

The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?

Laizure, S. C., Herring, V. L., Hu, Z., Witbrodt, K., & Parker, R. B. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1194 · Cited by 450 · see citing works

Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil

Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407 · see citing works

Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.

Humerickhouse, R. A., Lohrbach, K., Li, L., BOSRON, W. F., & Dolan, M. E. (2000) · PubMed · Cited by 353 · see citing works

In Vitro Glucuronidation Using Human Liver Microsomes and The Pore-Forming Peptide Alamethicin

Fisher, M. B., Campanale, K. M., Ackermann, B. L., VandenBranden, M. R., & Wrighton, S. A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15100-8 · Cited by 343 · see citing works

HUMAN UDP-GLUCURONOSYLTRANSFERASES: ISOFORM SELECTIVITY AND KINETICS OF 4-METHYLUMBELLIFERONE AND 1-NAPHTHOL GLUCURONIDATION, EFFECTS OF ORGANIC SOLVENTS, AND INHIBITION BY DICLOFENAC AND PROBENECID

Uchaipichat, V., Mackenzie, P. I., Guo, X.-H., Gardner-Stephen, D. A., Galetin, A., Houston, J. B., & Miners, J. O. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.4.413 · Cited by 337 · see citing works

GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P. C., & Parkinson, A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 331 · see citing works

Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.

Chauret, N., Gauthier, A., & Nicoll‐Griffith, D. A. (1998) · PubMed · Cited by 309 · see citing works

Prediction of Human Pharmacokinetics from Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300 · see citing works

Open "Back Door" in a Molecular Dynamics Simulation of Acetylcholinesterase

Gilson, M. K., Straatsma, T. P., McCammon, J. A., Ripoll, D. R., Faerman, C. H., Axelsen, P. H., Silman, I., & Sussman, J. L. (1994) · Science · doi:10.1126/science.8122110 · Cited by 265 · see citing works

Tissue-Specific mRNA Expression Profiles of Human Phase I Metabolizing Enzymes Except for Cytochrome P450 and Phase II Metabolizing Enzymes

Nishimura, M., & Naito, S. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.357 · Cited by 237 · see citing works

Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme

Bencharit, S., Morton, C. L., Xue, Y., Potter, P. M., & Redinbo, M. R. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb919 · Cited by 232 · see citing works

Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis

Zhu, H., Patrick, K. S., Yuan, H.-J., Wang, J. S., Donovan, J. L., DeVane, C. L., Malcolm, R. J., Johnson, J. A., Youngblood, G. L., Sweet, D. H., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.04.015 · Cited by 229 · see citing works

In Vitro Analysis of Human Drug Glucuronidation and Prediction of in Vivo Metabolic Clearance

Soars, M. G., Burchell, B., & Riley, R. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.382 · Cited by 229 · see citing works

In vitro–in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises

Miners, J. O., Knights, K., Houston, J. B., & Mackenzie, P. I. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.019 · Cited by 227 · see citing works

Conformation gating as a mechanism for enzyme specificity

Zhou, H., Wlodek, S. T., & McCammon, J. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9280 · Cited by 222 · see citing works

Drug-Metabolizing Ability of Molybdenum Hydroxylases

Kitamura, S., Sugihara, K., & Ohta, S. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.83 · Cited by 216 · see citing works

Keynote review: Mammalian carboxylesterases: From drug targets to protein therapeutics

Redinbo, M. R., & Potter, P. M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03383-0 · Cited by 213 · see citing works

Predicting Human Drug Glucuronidation Parameters: Application of In Vitro and In Silico Modeling Approaches

Miners, J. O., Smith, P. A., Sorich, M. J., McKinnon, R. A., & Mackenzie, P. I. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121546 · Cited by 210 · see citing works

Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

Kilford, P., Stringer, R., Sohal, B., Houston, J., & Galetin, A. (2009) · Drug Metabolism And Disposition · doi:10.1124/dmd.108.023853 · Cited by 201 · see citing works

Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation

Zhu, H.-J., Wang, X.-W., Gawronski, B. E., Brinda, B., Angiolillo, D., & Markowitz, J. S. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201640 · Cited by 189 · see citing works

The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities

Rowland, A., Knights, K., Mackenzie, P. I., & Miners, J. O. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021105 · Cited by 179 · see citing works

Crystal Structure of Human Carboxylesterase 1 Complexed with the Alzheimer's Drug Tacrine

Bencharit, S., Morton, C. L., Hyatt, J. L., Kühn, P., Danks, M. K., Potter, P. M., & Redinbo, M. R. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00071-1 · Cited by 174 · see citing works

The role of aldehyde oxidase in drug metabolism

Garattini, E., & Terao, M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.663352 · Cited by 174 · see citing works

Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation

Rowland, A., Gaganis, V., Elliot, D. J., Mackenzie, P. I., Knights, K., & Miners, J. O. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.118216 · Cited by 167 · see citing works

Structural insights into CPT-11 activation by mammalian carboxylesterases

Bencharit, S., Morton, C. L., Howard-Williams, E. L., Danks, M. K., Potter, P. M., & Redinbo, M. R. (2002) · Nature Structural Biology · doi:10.1038/nsb790 · Cited by 161 · see citing works

Proficient metabolism of irinotecan by a human intestinal carboxylesterase.

Khanna, R., Morton, C. L., Danks, M. K., & Potter, P. M. (2000) · PubMed · Cited by 158 · see citing works

THE EFFECT OF INCUBATION CONDITIONS ON THE ENZYME KINETICS OF UDP-GLUCURONOSYLTRANSFERASES

Soars, M. G., Ring, B. J., & Wrighton, S. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.762 · Cited by 152 · see citing works

Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors

Walsky, R. L., Bauman, J. N., Bourcier, K., Giddens, G., Lapham, K., Negahban, A., Ryder, T. F., Obach, R. S., Hyland, R., & Goosen, T. C. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.043117 · Cited by 151 · see citing works

Handbook of Drug Metabolism

(1999) · CRC Press eBooks · doi:10.1201/b13995 · Cited by 147 · see citing works

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

Tornio, A., Filppula, A. M., Kailari, O., Neuvonen, M., Nyrönen, T., Tapaninen, T., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.141 · Cited by 144 · see citing works

Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications

Diamond, S., Boer, J., Maduskuie, T. P., Falahatpisheh, N., Li, Y., & Yeleswaram, S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032375 · Cited by 138 · see citing works

Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

Cubitt, H. E., Houston, J., & Galetin, A. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9823-9 · Cited by 134 · see citing works

Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin

Gill, K. L., Houston, J., & Galetin, A. (2012) · Drug Metabolism And Disposition · doi:10.1124/dmd.111.043984 · Cited by 130 · see citing works

3 Molybdenum Hydroxylases: Biological Distribution and Substrate-Inhibitor Specificity

Beedham, C. (1987) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70420-x · Cited by 129 · see citing works

In Vitro-In Vivo Correlation for Intrinsic Clearance for Drugs Metabolized by Human Aldehyde Oxidase

Zientek, M. A., Jiang, Y., Youdim, K. A., & Obach, R. S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033555 · Cited by 127 · see citing works

Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data

Cubitt, H., Houston, J., & Galetin, A. (2011) · Drug Metabolism And Disposition · doi:10.1124/dmd.110.036566 · Cited by 125 · see citing works

In vitro–in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine

Boase, S., & Miners, J. O. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01669.x · Cited by 120 · see citing works

Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine.

Mistry, M., & Houston, J. B. (1987) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06808-4 · Cited by 120 · see citing works

Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes

Zientek, M. A., & Youdim, K. A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058750 · Cited by 113 · see citing works

Carboxylesterase inhibitors

Hatfield, M. J., & Potter, P. M. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.586339 · Cited by 113 · see citing works

Structure and function of mammalian aldehyde oxidases

Terao, M., Romão, M. J., Leimkühler, S., Bolis, M., Fratelli, M., Coelho, C., Santos-Silva, T., & Garattini, E. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1683-1 · Cited by 112 · see citing works

Increasing recognition of the importance of aldehyde oxidase in drug development and discovery

Garattini, E., & Terao, M. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.560606 · Cited by 111 · see citing works

UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: II. Functional Impact of the Three Most Common Nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S)

Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., Moltke, L. L., Greenblatt, D. J., & Court, M. H. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081968 · Cited by 108 · see citing works

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Liric Rajlic, I., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440282 · Cited by 106 · see citing works

Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 Cells for Recombinant Gene Expression: Application to a Rabbit Liver Carboxylesterase

Morton, C. L., & Potter, P. M. (2000) · Molecular Biotechnology · doi:10.1385/mb:16:3:193 · Cited by 104 · see citing works

Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.

Danks, M. K., Morton, C. L., Krull, E. J., Cheshire, P. J., Richmond, L. B., Naeve, C. W., Pawlik, C. A., Houghton, P. J., & Potter, P. M. (1999) · PubMed · Cited by 96 · see citing works

Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics

Benedetti, M. S., Whomsley, R., & Baltes, E. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.895 · Cited by 96 · see citing works

Species variation in hepatic aldehyde oxidase activity

Beedham, C., Bruce, S. E., Critchley, D. J. P., Al-Tayib, Y., & Rance, D. J. (1987) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03189919 · Cited by 96 · see citing works

Identification of UDP Glycosyltransferase 3A1 as a UDP N-Acetylglucosaminyltransferase

Mackenzie, P. I., Rogers, A., Treloar, J., Jorgensen, B. R., Miners, J. O., & Meech, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807961200 · Cited by 96 · see citing works

Drug-Drug Interactions

Flynn, E. J. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60037-6 · Cited by 96 · see citing works

Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11

Hatfield, M. J., Tsurkan, L. G., Garrett, M. R., Shaver, T. M., Hyatt, J. L., Edwards, C. C., Hicks, L. D., & Potter, P. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.09.001 · Cited by 95 · see citing works

Discovery of Novel Selective Inhibitors of Human Intestinal Carboxylesterase for the Amelioration of Irinotecan-Induced Diarrhea: Synthesis, Quantitative Structure-Activity Relationship Analysis, and Biological Activity

Wadkins, R. M., Hyatt, J. L., Yoon, K. J. P., Morton, C. L., Lee, R. E., Jr., Damodaran, K., Beroza, P., Danks, M. K., & Potter, P. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1336 · Cited by 95 · see citing works

Variation of Hepatic Methotrexate 7-Hydroxylase Activity in Animals and Humans

Kitamura, S., Sugihara, K., Nakatani, K., Ohta, S., Oh-hara, T., Ninomiya, S.-I., Green, C. E., & Tyson, C. A. (1999) · IUBMB Life · doi:10.1080/713803569 · Cited by 93 · see citing works

Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase

Coelho, C., Foti, A., Hartmann, T., Santos‐Silva, T., Leimkühler, S., & Romão, M. J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1895 · Cited by 92 · see citing works

The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.

Morton, C. L., Wadkins, R. M., Danks, M. K., & Potter, P. M. (1999) · PubMed · Cited by 91 · see citing works

Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans

Akabane, T., Tanaka, K., Irie, M., Terashita, S., & Teramura, T. (2011) · Xenobiotica · doi:10.3109/00498254.2010.549970 · Cited by 87 · see citing works

Activation of the Antiviral Prodrug Oseltamivir Is Impaired by Two Newly Identified Carboxylesterase 1 Variants

Zhu, H., & Markowitz, J. S. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024943 · Cited by 87 · see citing works

Drug Metabolism in Drug Design and Development

(2007) · Wiley eBooks · doi:10.1002/9780470191699 · Cited by 85 · see citing works

Pharmacokinetics and Molecular Detoxication

Cashman, J. R., Perotti, B. Y. T., Berkman, C. E., & Lin, J. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104s123 · Cited by 84 · see citing works

In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor

Zhang, X., Liu, H.-H., Weller, P. E., Zheng, M., Tao, W., Wang, J., Liao, G., Monshouwer, M., & Peltz, G. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.8 · Cited by 84 · see citing works

Time-Dependent Inactivation of P450 3A4 by Raloxifene: Identification of Cys239 as the Site of Apoprotein Alkylation1

Baer, B. R., Wienkers, L. C., & Rock, D. A. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700037e · Cited by 84 · see citing works

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State

Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Rajlic, I. L., & Obach, R. S. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440281 · Cited by 83 · see citing works

Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).

Potter, P. M., Pawlik, C. A., Morton, C. L., Naeve, C. W., & Danks, M. K. (1998) · PubMed · Cited by 78 · see citing works

Characterization of Aldehyde Oxidase Enzyme Activity in Cryopreserved Human Hepatocytes

Hutzler, J. M., Yang, Y.-S., Albaugh, D., Fullenwider, C. L., Schmenk, J., & Fisher, M. B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042861 · Cited by 78 · see citing works

Hydralazine As a Selective Probe Inactivator of Aldehyde Oxidase in Human Hepatocytes: Estimation of the Contribution of Aldehyde Oxidase to Metabolic Clearance

Strelevitz, T. J., Orozco, C. C., & Obach, R. S. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045195 · Cited by 77 · see citing works

The Novel UDP Glycosyltransferase 3A2: Cloning, Catalytic Properties, and Tissue Distribution

Mackenzie, P. I., Rogers, A., Elliot, D. J., Chau, N., Hulin, J.-A., Miners, J. O., & Meech, R. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.069336 · Cited by 76 · see citing works

Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining.

Moriwaki, Y., Yamamoto, T., Takahashi, S., Tsutsumi, Z., & Hada, T. (2001) · PubMed · doi:10.14670/hh-16.745 · Cited by 76 · see citing works

A species difference in the presystemic metabolism of carbazeran in dog and man

Kaye, B., Offerman, J. L., Reid, J. L., Elliott, H. L., & Hillis, W. S. (1984) · Xenobiotica · doi:10.3109/00498258409151492 · Cited by 73 · see citing works

Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences

Dalvie, D., Zhang, C., Chen, W., Smolarek, T. A., Obach, R. S., & Loi, C. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030783 · Cited by 72 · see citing works

Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human

Williams, E. T., Bacon, J. A., Bender, D. M., Lowinger, J. J., Guo, W., Ehsani, M. E., Wang, X., Wang, H., Qian, Y., Ruterbories, K. J., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041335 · Cited by 72 · see citing works

Selective Inhibition of Carboxylesterases by Isatins, Indole-2,3-diones

Hyatt, J. L., Moak, T., Hatfield, M. J., Tsurkan, L. G., Edwards, C. C., Wierdl, M., Danks, M. K., Wadkins, R. M., & Potter, P. M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061471k · Cited by 71 · see citing works

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration

Dittrich, C., Greim, G., Borner, M., Weigang-Köhler, K., Huisman, H., Amelsberg, A., Ehret, A., Wanders, J., Hanauske, A., & Fumoleau, P. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00020-5 · Cited by 71 · see citing works

Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.

Morton, C. L., Wierdl, M., Oliver, L., K, M., Danks, M. K., Stewart, C. F., Eiseman, J. L., & Potter, P. M. (2000) · PubMed · Cited by 69 · see citing works

Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction Monitoring

Fallon, J. K., Neubert, H., Goosen, T. C., & Smith, P. C. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053801 · Cited by 69 · see citing works

ALTERED AZT (3′-AZIDO-3′-DEOXYTHYMIDINE) GLUCURONIDATION KINETICS IN LIVER MICROSOMES AS AN EXPLANATION FOR UNDERPREDICTION OF IN VIVO CLEARANCE: COMPARISON TO HEPATOCYTES AND EFFECT OF INCUBATION ENVIRONMENT

Engtrakul, J. J., Foti, R., Strelevitz, T. J., & Fisher, M. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005058 · Cited by 68 · see citing works

Aldehyde Oxidase 1 (AOX1) in Human Liver Cytosols: Quantitative Characterization of AOX1 Expression Level and Activity Relationship

Fu, C., Di, L., Han, X., Soderstrom, C., Snyder, M., Troutman, M. D., Obach, R. S., & Zhang, H. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.053082 · Cited by 66 · see citing works

Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs

Nishimuta, H., Houston, J., & Galetin, A. (2014) · Drug Metabolism And Disposition · doi:10.1124/dmd.114.057372 · Cited by 66 · see citing works

Inhibition of Carboxylesterases by Benzil (Diphenylethane-1,2-dione) and Heterocyclic Analogues Is Dependent upon the Aromaticity of the Ring and the Flexibility of the Dione Moiety

Hyatt, J. L., Stacy, V., Wadkins, R. M., Yoon, K. J. P., Wierdl, M., Edwards, C. C., Zeller, M., Hunter, A. D., Danks, M. K., Crundwell, G., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0504196 · Cited by 66 · see citing works

Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide.

Sugihara, K., Kitamura, S., & Tatsumi, K. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07297-6 · Cited by 65 · see citing works

Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice

Morton, C. L., Iacono, L. C., Hyatt, J. L., Taylor, K. R., Cheshire, P. J., Houghton, P. J., Danks, M. K., Stewart, C. F., & Potter, P. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1027-y · Cited by 63 · see citing works

A Novel Reaction Mediated by Human Aldehyde Oxidase: Amide Hydrolysis of GDC-0834

Sodhi, J. K., Wong, S., Kirkpatrick, D. S., Liu, L., Khojasteh, S. C., Hop, C. E. C. A., Barr, J., Jones, J. P., & Halladay, J. S. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061804 · Cited by 63 · see citing works

Structure and evolution of vertebrate aldehyde oxidases: from gene duplication to gene suppression

Kurosaki, M., Bolis, M., Fratelli, M., Barzago, M. M., Pattini, L., Perretta, G., Terao, M., & Garattini, E. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1229-5 · Cited by 62 · see citing works

Individual Variation in Hepatic Aldehyde Oxidase Activity

Al-Salmy, H. S. (2001) · IUBMB Life · doi:10.1080/152165401753311799 · Cited by 62 · see citing works

Biochemical and molecular analysis of carboxylesterase‐mediated hydrolysis of cocaine and heroin

Hatfield, M., Tsurkan, L. G., Hyatt, J. L., Yu, X., Edwards, C., Hicks, L. D., Wadkins, R. M., & Potter, P. M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00700.x · Cited by 62 · see citing works

Modulation of Esterified Drug Metabolism by Tanshinones from Salvia miltiorrhiza (“Danshen”)

Hatfield, M. J., Tsurkan, L. G., Hyatt, J. L., Edwards, C. C., Lemoff, A. S., Jeffries, C. T., Yan, B., & Potter, P. M. (2013) · Journal of Natural Products · doi:10.1021/np300628a · Cited by 61 · see citing works

Structural Constraints Affect the Metabolism of 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by Carboxylesterases

Wadkins, R. M., Morton, C. L., Weeks, J. K., Oliver, L., Wierdl, M., Danks, M. K., & Potter, P. M. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.2.355 · Cited by 61 · see citing works

Improved, Selective, Human Intestinal Carboxylesterase Inhibitors Designed to Modulate 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) Toxicity

Hicks, L. D., Hyatt, J. L., Stoddard, S. V., Tsurkan, L. G., Edwards, C. C., Wadkins, R. M., & Potter, P. M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9001296 · Cited by 59 · see citing works

Effect of the β-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases

Oleson, L. E., & Court, M. H. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.9.0009 · Cited by 59 · see citing works

Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors

Tsurkan, L. G., Hatfield, M. J., Edwards, C. C., Hyatt, J. L., & Potter, P. M. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.10.018 · Cited by 51 · see citing works

An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11

Wierdl, M., Tsurkan, L. G., Hyatt, J. L., Edwards, C. C., Hatfield, M. J., Morton, C. L., Houghton, P. J., Danks, M. K., Redinbo, M. R., & Potter, P. M. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701112 · Cited by 50 · see citing works

Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach

Deguchi, T., Watanabe, N., Kurihara, A., Igeta, K., Ikenaga, H., Fusegawa, K., Suzuki, N., Murata, S., Hirouchi, M., Furuta, Y., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037457 · Cited by 47 · see citing works

Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan

Guemei, A. A. S., Cottrell, J., Band, R. A., Hehman, H., Prudhomme, M., Pavlov, M. V., Grem, J. L., Ismail, A. S., Bowen, D., Taylor, R. E., et al. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000258 · Cited by 46 · see citing works

Functional Analysis of UGT1A4 P24T and UGT1A4 L48V Variant Enzymes

Zhou, J., Argikar, U. A., & Remmel, R. P. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.105 · Cited by 46 · see citing works

Aldehyde Oxidase Activity in Donor-Matched Fresh and Cryopreserved Human Hepatocytes and Assessment of Variability in 75 Donors

Hutzler, J. M., Yang, Y.-S., Brown, C., Heyward, S. A., & Moeller, T. A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057984 · Cited by 46 · see citing works

Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates

Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M., & Yokoi, T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018705 · Cited by 45 · see citing works

Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity

Hyatt, J. L., Tsurkan, L. G., Wierdl, M., Edwards, C. C., Danks, M. K., & Potter, P. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0160 · Cited by 43 · see citing works

Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils

Hicks, L. D., Hyatt, J. L., Moak, T., Edwards, C. C., Tsurkan, L. G., Wierdl, M., Ferreira, A. M., Wadkins, R. M., & Potter, P. M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.012 · Cited by 41 · see citing works

Planarity and Constraint of the Carbonyl Groups in 1,2-Diones Are Determinants for Selective Inhibition of Human Carboxylesterase 1

Hyatt, J. L., Wadkins, R. M., Tsurkan, L. G., Hicks, L. D., Hatfield, M. J., Edwards, C. C., Ross, C. R., Cantalupo, S. A., Crundwell, G., Danks, M. K., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0706867 · Cited by 37 · see citing works

A quantitative approach to hepatic clearance prediction of metabolism by aldehyde oxidase using custom pooled hepatocytes

Akabane, T., Gerst, N., Masters, J. N., & Tamura, K. (2012) · Xenobiotica · doi:10.3109/00498254.2012.670736 · Cited by 36 · see citing works

Genomic analysis of the carboxylesterases: Identification and classification of novel forms

Williams, E. T., Wang, H., Wrighton, S. A., Qian, Y., & Perkins, E. J. (2010) · Molecular Phylogenetics and Evolution · doi:10.1016/j.ympev.2010.05.018 · Cited by 35 · see citing works

Unusual Glucuronides

Argikar, U. A. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045096 · Cited by 35 · see citing works

An experimental approach to enhance precursor ion fragmentation for metabolite identification studies: application of dual collision cells in an orbital trap

Dumouchel, J. L., & Argikar, U. A. (2011) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4996 · Cited by 34 · see citing works

Prediction of hepatic and intestinal glucuronidation using in vitro–in vivo extrapolation

Naritomi, Y., Nakamori, F., Furukawa, T. Y., & Tabata, K. (2014) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2014.10.001 · Cited by 34 · see citing works

Identification of a Novel N-Carbamoyl Glucuronide: In Vitro, In Vivo, and Mechanistic Studies

Gunduz, M., Argikar, U. A., Baeschlin, D. K., Ferreira, S. A., Hosagrahara, V. P., & Harriman, S. P. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030650 · Cited by 34 · see citing works

Identification of a suitable and selective inhibitor towards aldehyde oxidase catalyzed reactions

Nirogi, R. V. S., Kandikere, V. N., Palacharla, V. R. C., Bhyrapuneni, G., Kanamarlapudi, V. B., Ponnamaneni, R. K., & Manoharan, A. K. (2013) · Xenobiotica · doi:10.3109/00498254.2013.819594 · Cited by 30 · see citing works

Aldehyde Oxidase Activity in Fresh Human Skin

Manevski, N., Balavenkatraman, K. K., Bertschi, B., Swart, P., Walles, M., Camenisch, G., Schiller, H., Kretz, O., Ling, B. M., Wettstein, R., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060368 · Cited by 30 · see citing works

Comparative studies of mammalian acid lipases: Evidence for a new gene family in mouse and rat (Lipo)

Holmes, R. S., Cox, L. A., & VandeBerg, J. L. (2010) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2010.05.004 · Cited by 29 · see citing works

A Practical and Direct Comparison of Intrinsic Metabolic Clearance of Several Non-CYP Enzyme Substrates in Freshly Isolated and Cryopreserved Hepatocytes

Akabane, T., Gerst, N., Naritomi, Y., Masters, J. N., & Tamura, K. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rg-097 · Cited by 28 · see citing works

Inhibition of Human Aldehyde Oxidase Activity by Diet-Derived Constituents: Structural Influence, Enzyme-Ligand Interactions, and Clinical Relevance

Barr, J., Jones, J. P., Oberlies, N. H., & Paine, M. F. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061192 · Cited by 26 · see citing works

Structure−Activity Relationships of Substituted 1-Pyridyl-2-phenyl-1,2-ethanediones: Potent, Selective Carboxylesterase Inhibitors

Young, B. M., Hyatt, J. L., Bouck, D. C., Chen, T., Hanumesh, P., Price, J. E., Boyd, V. A., Potter, P. M., & Webb, T. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101101q · Cited by 26 · see citing works

Cynomolgus Monkey as a Surrogate for Human Aldehyde Oxidase Metabolism of the EGFR Inhibitor BIBX1382

Hutzler, J. M., Cerny, M. A., Yang, Y.-S., Asher, C. O., Wong, D. F., Frederick, K. S., & Gilpin, K. E. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059030 · Cited by 26 · see citing works

Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition

Hu, Z.-Y., Edginton, A. N., Laizure, S. C., & Parker, R. B. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0160-3 · Cited by 25 · see citing works

Plasma pharmacokinetics of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial

Kestell, P., Dunlop, I. C., McCrystal, M. R., Evans, B., Paxton, J. W., Gamage, R. S. K. A., & Baguley, B. C. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050943 · Cited by 24 · see citing works

Reduction and methylation of ziprasidone by glutathione, aldehyde oxidase, and thiol s-methyltransferase in humans: anin vitrostudy

Obach, R. S., Prakash, C., & Kamel, A. M. (2012) · Xenobiotica · doi:10.3109/00498254.2012.683203 · Cited by 24 · see citing works

Effect of Tea Beverages on Aldehyde Oxidase Activity

Tayama, Y., Sugihara, K., Sanoh, S., Miyake, K., MORITA, S., Kitamura, S., & Ohta, S. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-nt-078 · Cited by 23 · see citing works

Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones

Parkinson, E. I., Hatfield, M. J., Tsurkan, L. G., Hyatt, J. L., Edwards, C. C., Hicks, L. D., Yan, B., & Potter, P. M. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.012 · Cited by 23 · see citing works

Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans

Gibson, C., Lu, P., Maciolek, C., Wudarski, C., Barter, Z., Rowland-Yeo, K., Stroh, M., Lai, E., & Nicoll-Griffith, D. (2013) · Xenobiotica; the fate of foreign compounds in biological systems · doi:10.3109/00498254.2013.791761 · Cited by 22 · see citing works

Rationalizing Underprediction of Drug Clearance from Enzyme and Transporter Kinetic Data: From In Vitro Tools to Mechanistic Modeling

Galetin, A. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-758-7_13 · Cited by 21 · see citing works

Conjugative Metabolism of Drugs

Remmel, R. P., Nagar, S., & Argikar, U. A. (2007) · doi:10.1002/9780470191699.ch3 · Cited by 21 · see citing works

Identification of a new allele of Es-1 segregating in an inbred strain of mice

Soares, E. R. (1979) · Biochemical Genetics · doi:10.1007/bf00502119 · Cited by 14 · see citing works

Evaluation of Pharmaceutical Excipients as Cosolvents in 4-Methyl Umbelliferone Glucuronidation in Human Liver Microsomes: Applications for Compounds with Low Solubility

Argikar, U. A., Liang, G., Dumouchel, J. L., Hosagrahara, V. P., & Lee, W. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-sh-086 · Cited by 13 · see citing works

Identification of saturated and unsaturated fatty acids released during microsomal incubations

Dumouchel, J. L., Liang, G., Dunne, C. E., Harriman, S. P., & Argikar, U. A. (2014) · Xenobiotica · doi:10.3109/00498254.2014.884253 · Cited by 13 · see citing works

UDP-Glucuronic Acid Binds First and the Aglycone Substrate Binds Second to Form a Ternary Complex in UGT1A9-Catalyzed Reactions, in Both the Presence and Absence of Bovine Serum Albumin

Manevski, N., Yli‐Kauhaluoma, J. T., & Finel, M. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047746 · Cited by 13 · see citing works

The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics

Di, L. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180821094502 · Cited by 211 · see citing works

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142 · see citing works

Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling

Kratochwil, N. A., Meille, C., Fowler, S. M., Klammers, F., Ekiciler, A., Molitor, B., Simon, S., Walter, I., McGinnis, C., Walther, J., et al. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0019-7 · Cited by 111 · see citing works

Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery

Manevski, N., King, L. M., Pitt, W. R., Lecomte, F., & Toselli, F. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00875 · Cited by 108 · see citing works

Drug metabolism and metabolite safety assessment in drug discovery and development

He, C., & Wan, H. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1519546 · Cited by 92 · see citing works

Aldehyde oxidase and its role as a drug metabolizing enzyme

Dalvie, D., & Di, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.011 · Cited by 90 · see citing works

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues

Teschke, R., & Uetrecht, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-2020-ubih-05 · Cited by 61 · see citing works

Primary Human Hepatocyte Spheroids as an In Vitro Tool for Investigating Drug Compounds with Low Hepatic Clearance

Riede, J., Wollmann, B. M., Molden, E., & Ingelman‐Sundberg, M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000340 · Cited by 53 · see citing works

Predicting mammalian metabolism and toxicity of pesticides in silico

Clark, R. D. (2018) · Pest Management Science · doi:10.1002/ps.4935 · Cited by 51 · see citing works

Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways

Toselli, F., Fredenwall, M., Svensson, P., Li, X., Johansson, A., Weidolf, L. O. G., & Hayes, M. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00030 · Cited by 43 · see citing works

Prediction of Total Drug Clearance in Humans Using Animal Data: Proposal of a Multimodal Learning Method Based on Deep Learning

Iwata, H., Matsuo, T., Mamada, H., Motomura, T., Matsushita, M., Fujiwara, T., Maeda, K., & D, K. H. M. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.01.020 · Cited by 42 · see citing works

Predicting liver cytosol stability of small molecules

Shah, P., Siramshetty, V. B., Zakharov, A. V., Southall, N. T., Xu, X., & Nguyễn, Ð.-T. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00426-7 · Cited by 37 · see citing works

A Targeted LC-MS/MS Proteomics-Based Strategy to Characterize In Vitro Models Used in Drug Metabolism and Transport Studies

Xu, M.-J., Saxena, N., Vrana, M., Zhang, H., Kumar, V., Billington, S., Khojasteh, C., Heyward, S., Unadkat, J., & Prasad, B. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01913 · Cited by 34 · see citing works

Aldehyde oxidase; new approaches to old problems

Beedham, C. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1626029 · Cited by 32 · see citing works

ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension

Montagnoli, T. L., da Silva, J. S., Sudo, S. Z., Santos, A. D., Gomide, G. F., de Sá, M. P. L., & Zapata‐Sudo, G. (2021) · Cells · doi:10.3390/cells10071648 · Cited by 31 · see citing works

Evaluation of Carbazeran 4-Oxidation and O6-Benzylguanine 8-Oxidation as Catalytic Markers of Human Aldehyde Oxidase: Impact of Cytosolic Contamination of Liver Microsomes

Xie, J., Saburulla, N. F., Chen, S., Wong, S. Y., Yap, Z. P., Zhang, L. H., & Lau, A. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.082099 · Cited by 30 · see citing works

Rifampin modulation of xeno‐ and endobiotic conjugating enzyme mRNA expression and associated micro RNA s in human hepatocytes

Gufford, B. T., Robarge, J., Eadon, M. T., Gao, H., Lin, H., Liu, Y., Desta, Z., & Skaar, T. C. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.386 · Cited by 29 · see citing works

An overview of aldehyde oxidase: an enzyme of emerging importance in novel drug discovery

Rashidi, M., & Soltani, S. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1284198 · Cited by 29 · see citing works

In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes

Docci, L., Klammers, F., Ekiciler, A., Molitor, B., Umehara, K., Walter, I., Krähenbühl, S., Parrott, N. J., & Fowler, S. M. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00482-9 · Cited by 28 · see citing works

Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs)

Zhou, J., Argikar, U. A., & Miners, J. O. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_12 · Cited by 27 · see citing works

Ocular non-P450 oxidative, reductive, hydrolytic, and conjugative drug metabolizing enzymes

Argikar, U. A., Dumouchel, J. L., Dunne, C. E., & Bushee, A. J. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1322609 · Cited by 27 · see citing works

Critical overview on the structure and metabolism of human aldehyde oxidase and its role in pharmacokinetics

Mota, C., Coelho, C., Leimkühler, S., Garattini, E., Terao, M., Santos‐Silva, T., & Romão, M. J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.04.006 · Cited by 26 · see citing works

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates

Reddy, M. B., Bolger, M. B., Fraczkiewicz, G., Frari, L. D., Luo, L., Lukáčová, V., Mitra, A., Macwan, J. S., Mullin, J. M., Parrott, N. J., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091325 · Cited by 23 · see citing works

Aldehyde oxidase mediated drug metabolism: an underpredicted obstacle in drug discovery and development

Gajula, S. N. R., Nathani, T. N., Patil, R. M., Talari, S., & Sonti, R. (2022) · Drug Metabolism Reviews · doi:10.1080/03602532.2022.2144879 · Cited by 23 · see citing works

Cytosolic Enzymes Generate Cannabinoid Metabolites 7-Carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol

Beers, J. L., Authement, A. K., Isoherranen, N., & Jackson, K. D. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00017 · Cited by 22 · see citing works

Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate

Hou, X., Zhou, J., Yu, S., Zhou, L., Zhang, Y., Zhong, D., & Chen, X. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.081182 · Cited by 22 · see citing works

Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine

Docci, L., Umehara, K., Krähenbühl, S., Fowler, S. M., & Parrott, N. J. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00513-5 · Cited by 23 · see citing works

Aldehyde oxidase-dependent species difference in hepatic metabolism of fasudil to hydroxyfasudil

Mao, Z., Wu, Y., Li, Q., Wang, X., Liu, Y., & Di, X. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1292016 · Cited by 21 · see citing works

Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter–Enzyme Interplay

Matsunaga, N., Fukuchi, Y., Imawaka, H., & Tamai, I. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079236 · Cited by 21 · see citing works

New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation

Gunduz, M., Argikar, U. A., Cirello, A. L., & Dumouchel, J. L. (2018) · Drug Metabolism Letters · doi:10.2174/1872312812666180611113656 · Cited by 19 · see citing works

Aldehyde oxidase at the crossroad of metabolism and preclinical screening

Cheshmazar, N., Dastmalchi, S., Terao, M., Garattini, E., & Hamzeh‐Mivehroud, M. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1667379 · Cited by 18 · see citing works

Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture

Chan, T. S., Scaringella, Y.-S., Raymond, K. G., & Taub, M. E. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090951 · Cited by 18 · see citing works

Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes

Takahashi, R., Forrest, W. F., Smith, A. D., Badée, J., Qiu, N., Schmidt, S., Collier, A. C., Parrott, N. J., & Fowler, S. M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000474 · Cited by 18 · see citing works

Human Liver Microsomes Immobilized on Magnetizable Beads: A Novel Approach to Study In Vitro Drug Metabolism

Horspool, A. M., Wang, T., Scaringella, Y.-S., Taub, M. E., & Chan, T. S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090696 · Cited by 17 · see citing works

Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors

Liu, S. N., Lu, J. B. L., Watson, C. J. W., Lazarus, P. J., Desta, Z., & Gufford, B. T. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085035 · Cited by 17 · see citing works

Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation

Busse, D., Leandersson, S., Amberntsson, S., Darnell, M., & Hilgendorf, C. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.03.013 · Cited by 15 · see citing works

Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults

Yang, X., Duan, J. Z., & Fisher, J. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164641 · Cited by 15 · see citing works

Discovery of blood-brain barrier permeable and orally bioavailable caffeine-based amide derivatives as acetylcholinesterase inhibitors

Sharma, M., Sharma, A., Thakur, S., Nuthakki, V. K., Jamwal, A., Nandi, U., Jadhav, H. R., & Bharate, S. B. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106719 · Cited by 13 · see citing works

Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation

Izat, N., Bolleddula, J., Abbasi, A., Cheruzel, L., Jones, R. S., Moss, D., Ortega-Muro, F., Parmentier, Y., Peterkin, V. C., Tian, D.-D., et al. (2023) · Drug Metabolism And Disposition · doi:10.1124/dmd.123.001436 · Cited by 13 · see citing works

Physiologically-Based Pharmacokinetic Modeling for Drugs Cleared by Non-Cytochrome P450 Enzymes: State-of-the-Art and Future Perspectives

Ozbey, A. C., Fowler, S. M., Leys, K., Annaert, P., Umehara, K., & Parrott, N. J. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001487 · Cited by 13 · see citing works

CYP-Mediated Sulfoximine Deimination of AZD6738

Jones, B., Markandu, R., Gu, C., & Scarfe, G. B. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.077776 · Cited by 13 · see citing works

Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics

Howard, M., Barber, J., Alizai, N. K., & Rostami‐Hodjegan, A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1546288 · Cited by 13 · see citing works

A comprehensive review of in silico approaches for the prediction and modulation of aldehyde oxidase-mediated drug metabolism: The current features, challenges and future perspectives

Soltani, S., Hallaj‐Nezhadi, S., & Rashidi, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113559 · Cited by 12 · see citing works

Ontogeny of Human Liver Aldehyde Oxidase: Developmental Changes and Implications for Drug Metabolism

Subash, S., Singh, D. K., Ahire, D. S., Khojasteh, S. C., Murray, B. P., Zientek, M. A., Jones, R. S., Kulkarni, P., Zubair, F., Smith, B. J., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c01147 · Cited by 11 · see citing works

In Vitro and In Vivo Pharmacokinetic Characterization of 7-Hydroxymitragynine, an Active Metabolite of Mitragynine, in Sprague-Dawley Rats

Chiang, Y., Kanumuri, S. R. R., Kuntz, M. A., Senetra, A. S., Berthold, E. C., Kamble, S. H., Mukhopadhyay, S., Hampson, A. J., McCurdy, C. R., & Sharma, A. (2025) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-025-00939-2 · Cited by 11 · see citing works

Recent developments in predicting CYP-independent metabolism

Dhuria, N. V., Haro, B., Kapadia, A. K. B., Lobo, K. A., Matusow, B., Schleiff, M. A., Tantoy, C., & Sodhi, J. K. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1923728 · Cited by 11 · see citing works

Design, synthesis, and metabolite identification of Tamoxifen esterase-activatable prodrugs

Elbagoury, R. M., Shenouda, M. A., El-Nakib, H. E., Wober, J., Abadi, A., & Ahmed, N. S. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106303 · Cited by 11 · see citing works

When Cofactors Aren’t X Factors: Functional Groups That Are Labile in Human Liver Microsomes in the Absence of NADPH

Landry, M. L., Trager, R., Broccatelli, F., & Crawford, J. J. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00071 · Cited by 10 · see citing works

Metabolic Activation of Cholestatic Drug-Induced Bile Acid-Dependent Toxicity in Human Sandwich-Cultured Hepatocytes

Ogimura, E., Tokizono, M., Sekine, S., Nakagawa, T., Bando, K., & Ito, K. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.050 · Cited by 10 · see citing works

Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors

den Braver-Sewradj, S. P., den Braver, M. W., Baze, A., Decorde, J., Fonsi, M., Bachellier, P., Vermeulen, N. P. E., Commandeur, J. N. M., Richert, L., & Vos, J. C. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.07.032 · Cited by 10 · see citing works

Transforming drug discovery: the impact of AI and molecular simulation on R&D efficiency

Iwata, H. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2437283 · Cited by 9 · see citing works

Dissecting Parameters Contributing to the Underprediction of Aldehyde Oxidase-Mediated Metabolic Clearance of Drugs

Subash, S., Singh, D. K., Ahire, D. S., Khojasteh, S. C., Murray, B. P., Zientek, M. A., Jones, R. S., Kulkarni, P., Smith, B. J., Heyward, S. A., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001379 · Cited by 8 · see citing works

HLM-beads: Rapid Assessment of Nonspecific Binding to Human Liver Microsomes Using Magnetizable Beads

Wang, T., Whitcher‐Johnstone, A., Keith-Luzzi, M., & Chan, T. S. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000575 · Cited by 7 · see citing works

In vitro metabolism of olaparib in liver microsomes by liquid chromatography/electrospray ionization high‐resolution mass spectrometry

Wang, L., & Wang, M. (2019) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8575 · Cited by 7 · see citing works

Novel advances in biotransformation and bioactivation research – 2020 year in review

Khojasteh, S. C., Argikar, U. A., Driscoll, J. P., Heck, C. J. S., King, L. M., Jackson, K. D., Jian, W., Kalgutkar, A. S. S., Miller, G. P., Kramlinger, V. M., et al. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1916028 · Cited by 7 · see citing works

Comparison of Relative Activity versus Relative Expression Factors (RAF versus REF) in Predicting Glucuronidation Mediated Drug Clearance Using Recombinant UGTs

Subash, S., Ahire, D. S., Patel, M., Shaikh, S., Singh, D. K., Deshmukh, S. V., & Prasad, B. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03750-x · Cited by 6 · see citing works

Glucuronidation

Pan, Y. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016414-00278 · Cited by 5 · see citing works

Identification of selective inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A3 and UGT1A8 and their application in UGT reaction phenotyping studies in human liver and intestinal microsomes

Wang, T., Anderson, A. P., Yu, A. S., Taub, M. E., & Chan, T. S. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100058 · Cited by 5 · see citing works

Cytochrome P450: In Vitro Methods and Protocols

Yan, Z., & Caldwell, G. W. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1542-3_1 · Cited by 5 · see citing works

Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Prins, H. A. B., Zino, L., Svensson, E. M., Verbon, A., de Bree, G. J., Prins, J. M., Reiss, P., Burger, D. M., Rokx, C., & Colbers, A. P. H. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106697 · Cited by 5 · see citing works

MicroRNAs mediate liver transcriptome changes upon soy diet intervention in mice

Șeclăman, E. P., Bălăcescu, L., Bălăcescu, O., Bejinar, C., Udrescu, M., Marian, C., Sîrbu, I. O., & Anghel, A. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14140 · Cited by 5 · see citing works

Identification of Catalposide Metabolites in Human Liver and Intestinal Preparations and Characterization of the Relevant Sulfotransferase, UDP-glucuronosyltransferase, and Carboxylesterase Enzymes

Hwang, D.-K., Kim, J., Shin, Y., Choi, W.-G., Kim, S., Cho, Y., Lee, J. Y., Kang, H. C., & Lee, H. S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070355 · Cited by 5 · see citing works

Quantitative prediction of drug disposition for uridine diphosphate-glucuronosyltransferase substrates using humanized mice

Miyake, T., Fujita, Y., Hirabayashi, M., Komiyama, N., Morita, K., Tachibana, T., & Terao, K. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100050 · Cited by 4 · see citing works

Preclinical pharmacokinetic studies of villocarine A, an active Uncaria alkaloid

Chiang, Y., Chear, N. J., Berthold, E. C., Kuntz, M. A., Kanumuri, S. R. R., Senetra, A. S., Ramanathan, S., McCurdy, C. R., & Sharma, A. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3703 · Cited by 4 · see citing works

Effects of Phenothiazines on Aldehyde Oxidase Activity Towards Aldehydes and N-Heterocycles: an In Vitro and In Silico Study

Deris-Abdolahpour, F., Abdolalipouran-Sadegh, L., Dastmalchi, S., Hamzeh‐Mivehroud, M., Zarei, O., Dehgan, G., & Rashidi, M. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0514-6 · Cited by 4 · see citing works

Identification of non-P450 enzymes involved in the metabolism of new drugs: Their significance in drug interaction evaluation and prodrug disposition

Nishiya, Y., Suzuki, E., Ishizuka, T., Kazui, M., Sakurai, H., & Nakai, D. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.11.001 · Cited by 4 · see citing works

Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase

Paragas, E. M., Choughule, K. V., Jones, J. P., & Barr, J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1554-6_10 · Cited by 4 · see citing works

Aminobenzotriazole inhibits and induces several key drug metabolizing enzymes complicating its utility as a pan CYP inhibitor for reaction phenotyping

Aluri, K. C., Slavsky, M., Tan, Y., Whitcher‐Johnstone, A., Zhang, Z., Hariparsad, N., & Ramsden, D. (2024) · Clinical and Translational Science · doi:10.1111/cts.13746 · Cited by 3 · see citing works

In-vitro metabolism of LXY18, an orally available, potent blocker of AURKB relocation in mitosis

Li, J., Choudhry, N., Lv, G., Naganna, N., Reddy, M. C., Liu, H. S., Allen, T. D., Zhang, J., & Yang, D. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115415 · Cited by 4 · see citing works

Drug transporters in drug disposition – highlights from the year 2023

Chothe, P. P., Argikar, U. A., Mitra, P., Nakakariya, M., Ramsden, D., Rotter, C. J., Sandoval, P., & Tohyama, K. (2024) · Drug Metabolism Reviews · doi:10.1080/03602532.2024.2399523 · Cited by 3 · see citing works

Examining Physiologically Based Pharmacokinetic Model Assumptions for Cross-Tissue Similarity of Activity per Unit of Enzyme: The Case Example of Uridine 5′-Diphosphate Glucuronosyltransferase

Ahmed, A. N., Rostami‐Hodjegan, A., Barber, J., & Al‐Majdoub, Z. M. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000813 · Cited by 3 · see citing works

Directing the Metabolism of Drugs Away from CYP450: The Use of Oxetane Rings

Raffa, R. B., & Pergolizzi, J. V. (2019) · Pharmacology &amp Pharmacy · doi:10.4236/pp.2019.1011038 · Cited by 3 · see citing works

Preclinical Studies to Enable First in Human Clinical Trials

Chopra, R., & Raynaud, F. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_3 · Cited by 3 · see citing works

Elucidating a Complicated Enantioselective Metabolic Profile: A Study From Rats to Humans Using Optically Pure Doxazosin

Kong, D., Tian, Y. Y., Duan, K., Guo, W., Zhang, Q., Zhang, P., Yang, Z., Qin, X., Ren, L., & Zhang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.834897 · Cited by 2 · see citing works

Evaluation of Fentanyl-Emerged Adverse Events and Pharmacokinetics in Neonates: A Physiologically Based Pharmacokinetic Modeling Approach

Mahdy, W. Y. B., Yamamoto, K., Joji, R., Hashimoto, M., Nakasone, R., Fujioka, K., Itohara, K., Kitahiro, Y., Omura, T., & Yano, I. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01573-6 · Cited by 2 · see citing works

Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib

Lewis, G. J., Jewell, R. C., Krishnatry, A. S., & Taskar, K. S. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70182 · Cited by 2 · see citing works

Investigating the link between drug metabolism and toxicity

Humphreys, W. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00027-1 · Cited by 2 · see citing works

Pharmacokinetic, Pharmacodynamic, Preclinical and Clinical Models for Evaluation of Nanoparticles

Gharat, S., Momin, M. M., & Khan, T. A. (2024) · Springer eBooks · doi:10.1007/978-981-99-7858-8_3 · Cited by 2 · see citing works

Drug development

Raynaud, F. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812784-1.00009-8 · Cited by 2 · see citing works

The Importance of Metabolite Pharmacokinetics Studies in Drug Development

Zhou, J. M., & Ma, Y. (2018) · International Journal of Pharmacokinetics · doi:10.4155/ipk-2017-0020 · Cited by 1 · see citing works

Uridine 5′-Diphospho-glucuronosyltransferase 1A3 (UGT1A3) Prediction of Hepatic Clearance of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Substrate Telmisartan by Glucuronidation Using In Vitro–In Vivo Extrapolation (IVIVE)

Gabor-Worwa, E., Kowal-Chwast, A., Gaud, N., Gogola, D., Littlewood, P., Smoluch, M. T., Brzózka, K. D., & Kuś, K. (2024) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-024-00895-3 · Cited by 1 · see citing works

Drug Metabolizing Enzymes and Transporters of the Mesentery

Argikar, A. A., & Argikar, U. A. (2023) · Progress in inflammation research · doi:10.1007/978-3-031-17774-3_10 · Cited by 1 · see citing works

Using in vitro methods to determine P450s responsible for metabolism and discrimination from other oxidative pathways

Fretland, A. J., Bapiro, T. E., Jones, B., Markandu, R., Orton, A. L., & Reddy, V. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820018-6.00007-7

Drug Metabolism/Transport and Pharmacokinetics

Song, I.-S. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-2458-0

RESOLVING THE CHALLENGES TO ESTABLISHING CONFIDENCE IN PBPK MODELS

Peters, S. A. (2021) · doi:10.1002/9781119497813.ch19

Principles of Drug Metabolism

Dalvie, D., & Testa, B. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc033.pub3

Additional file 3 of Predicting liver cytosol stability of small molecules

Shah, P., Siramshetty, V. B., Zakharov, A. V., Southall, N. T., Xu, X., & Nguyễn, Ð.-T. (2020) · Figshare · doi:10.6084/m9.figshare.12096588

Additional file 2 of Predicting liver cytosol stability of small molecules

Shah, P., Siramshetty, V. B., Zakharov, A. V., Southall, N. T., Xu, X., & Nguyễn, Ð.-T. (2020) · Figshare · doi:10.6084/m9.figshare.12096585

Additional file 1 of Predicting liver cytosol stability of small molecules

Shah, P., Siramshetty, V. B., Zakharov, A. V., Southall, N., Xu, X., & Nguyen, D.-T. (2020) · Figshare · doi:10.6084/m9.figshare.12096579

Inhibitory effects of hinokiflavone on human liver cytochrome P450 enzymes

Han, N., & Jiang, D. (2026) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2026.102080

Pharmacokinetics and Brain Distribution of a Purine-Derived Neuroprotective Agent after Intranasal Administration in Neonatal Rats with Hypoxic–Ischemic Brain Injury

Maïza, A., Disdier, C., Tsintzou, A., Nguyen, A. L., Pruvost, A., Théodoro, F., Zang, Z., Wang, B., Oumata, N., Galons, H., et al. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04163-8

BindingDB Entry 50019062: Cytosolic Enzymes Generate Cannabinoid Metabolites 7-Carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol.

BindingDB (2024) · UC San Diego · doi:10.7270/q2pv6qnx

Recent developments in predicting CYP-independent metabolism

Dhuria, N. V., Haro, B., Kapadia, A. K. B., Lobo, K. A., Matusow, B., Schleiff, M. A., Tantoy, C., & Sodhi, J. K. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1923728 · Cited by 11 · see citing works

Evaluation of the clearance mechanism of non-CYP-mediated drug metabolism and DDI as a victim drug

Ghosal, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820018-6.00008-9 · Cited by 1 · see citing works

Cytochrome P450 and Non–Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics

Foti, R., & Dalvie, D. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071753 · Cited by 117 · see citing works

Non-Cytochrome P450 Enzymes and Glucuronidation

Hutzler, J. M., & Zientek, M. A. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622376-00079 · Cited by 1 · see citing works

Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of

Enzymes, D.-M., Zientek, M. A., & Youdim, K. A. (2014)